Totally Implantable Hearing Implant Revision Surgery Indications and Outcomes.


Journal

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504

Informations de publication

Date de publication:
01 04 2023
Historique:
pubmed: 11 2 2023
medline: 24 3 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

Analyze indications, findings, and outcomes of revision procedures for a totally implantable active middle ear implant (AMEI) over the past 17 years. Retrospective review. Single institution, private practice setting. Adult patients using a totally implantable AMEI called the Esteem middle ear implant by Envoy Medical who needed revision to their original implant between 2005 and 2022. Thirty-nine patients had 60 revision procedures. History of a totally implantable AMEI revision procedure. Indications for revision were related to either surgical wound issues or reduced device function. Device diagnostics, audiometric outcomes, and documented subjective report. Surgical site wound issues were readily corrected in the majority of patients; most had risk factors for wound breakdown. For sterile wound dehiscence, it was not always necessary to remove the sound processor for an extended time to promote healing. Outcomes for revision procedures because of device issues ranged from 31 to 100% success rate, depending on the cause of issue. The most common indication for revision was reduced device function caused by scar band and/or fibrotic tissue accumulation in the middle ear. Revision of fully implantable AMEI can be successful for many indications. Appropriate preoperative device troubleshooting and medical evaluation is helpful in identifying the issue and determining surgical approach. Suboptimal device function and feedback can sometimes be improved by removing tissue around the implant, although permanency of this procedure varies among patients.

Identifiants

pubmed: 36764704
doi: 10.1097/MAO.0000000000003820
pii: 00129492-202304000-00017
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-372

Informations de copyright

Copyright © 2023, Otology & Neurotology, Inc.

Déclaration de conflit d'intérêts

J.S. is a consultant for Envoy Medical. The remaining authors disclose no conflicts of interest.

Références

Marzo SJ, Sappington JM, Shohet JA. The Envoy Esteem implantable hearing system. Otolaryngol Clin North Am 2014;47:941–52.
Kraus EM, Shohet JA, Catalano PJ. Envoy Esteem Totally Implantable Hearing System: Phase 2 trial, 1-year hearing results. Otolaryngol Head Neck Surg 2011;145:100–9.
Shohet JA, Gende DM, Tanita CS. Totally implantable active middle ear implant: Hearing and safety results in a large series. Laryngoscope 2018;128:2872–8.
Shohet JA, Kraus EM, Catalano PJ, Toh E. Totally implantable hearing system: Five-year hearing results. Laryngoscope 2018;128:210–6.

Auteurs

Jack Shohet (J)

Shohet Ear Associates, Newport Beach, California.

Jacqueline Bibee (J)

Shohet Ear Associates, Newport Beach, California.

Deanna Gende (D)

Orange County Physicians' Hearing Services.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH